NCT05395702View on ClinicalTrials.gov

Study of Ingaron's Effect on Efficacy and Resistance to Antibiotics in Community-acquired Pneumonia

NACompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

May 12, 2017

Primary Completion Date

July 27, 2018

Study Completion Date

May 30, 2019

Conditions
Community-acquired Pneumonia
Interventions
DRUG

Interferon-Gamma

received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein

Trial Locations (1)

121374

City Clinical Hospital named after M.E. Zhadkevich Moscow City Health Department, Moscow

All Listed Sponsors
lead

SPP Pharmaclon Ltd.

INDUSTRY

NCT05395702 - Study of Ingaron's Effect on Efficacy and Resistance to Antibiotics in Community-acquired Pneumonia | Biotech Hunter | Biotech Hunter